Hydra Biosciences is a privately held clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that develops drugs to treat pain, inflammation, renal disease, anxiety and pulmonary disease using its expertise in novel ion channels. Hydra Biosciences’ proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $10.5M
Founded date: 2001
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Accelerati... | accelerati... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.03.2015 | Series E | $10.5M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 03.01.2018 | Centrexion’s $67M Series D round to fund Phase 3 pain studie... | Despite being just four years old, Centrexion is building a significant pipeline of non-opioid, non-... | medcitynew... |
| 10.02.2015 | Looks like BioVentures is in the midst of raising a new $100... | The venture firm typically invests $3 million to $10 million, it says, and does operate like your ty... | medcitynew... |
| 10.04.2011 | A key to birth control pills for men | By Nancy Fliesler It’s found only in the tails of sperm. It takes seven genes to build it. It gets... | massdevice... |
| 12.12.2008 | Biogen Idec VC Group Sees Opportunity in Tough Market, Has $... | Share Share on Facebook Share on Twitter LinkedIn Email Reprints It’s tough times for biotech entre... | xconomy.co... |
| - | Looks like BioVentures is in the midst of raising a new $100... | Hey, life science startups: Looks like Massachusetts investment firm BioVentures is raising a new ve... | medcitynew... |
| - | Centrexion’s $67M Series D round to fund Phase 3 pain studie... | Boston-based Centrexion Therapeutics has finalized $67 million in Series D financing to fund upcomin... | medcitynew... |